Do you know the symptoms of spinal muscular atrophy?

Urgent referral and treatment is crucial to give families the best chance of improved outcomes

This content has been independently produced by ADG, made possible through sponsorship from Biogen.

New treatment advances mean that urgent referral to a neurologist is crucial in infants with spinal muscular atrophy (SMA).

The disease is a leading genetic cause of death of infants aged under two. But, early treatment can delay disease progression, according to recent studies, a GP education campaign launched by the RACGP and a ThinkGP educational module.

“SMA is now a treatable condition. There is an approved therapy on the PBS [Spinraza (nusinersen)], and there are probably other treatments that will be available in the next few years,” says Dr Anita Cairns, a Queensland-based paediatric neurologist.